Comparison of HER2 detection methods between central and regional laboratories in Greece

Clinical Breast Cancer

Volumn 7, Issue 10, 2007, Pages 784-790

  Papadopoulos, Savvas ^a   Kouvatseas, George ^b   Skarlos, Dimosthenis ^c   Malamos, Nikolaos ^d   Delliou, Eleftheria ^a   Saratsiotou, Ioanna ^e   Ardavanis, Alexandros ^e   Mavroudis, Dimitrios ^f   Skarpidi, Evangelia ^a   Arapantoni, Petroula ^g   Karyda, Irini ^a   Patakioyta, Frideriki ^h   Aravantinos, Gerasimos ⁱ   Razis, Evangelia ^a   Fountzilas, George ^j   Kosmidis, Paris ^a  

^a HYGEIA HOSPITAL   (Greece)

^b ATHENS UNIVERSITY OF ECONOMICS AND BUSINESS   (Greece)

^c Henry Dunan Hospital   (Greece)

^d HELENA VENIZELOU HOSPITAL   (Greece)

^e Agios Savvas Anticancer Hospital   (Greece)

^f UNIVERSITY OF CRETE   (Greece)

^g METAXA CANCER HOSPITAL   (Greece)

^h THEAGENIO CANCER HOSPITAL   (Greece)

ⁱ Agii Anargiri Anticancer Hospital   (Greece)

^j ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

more..

Author keywords

Fluorescence in situ hybridization; HER2 neu; Immunohistochemistry

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST CANCER; CANCER PATIENT; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE IDENTIFICATION; GREECE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROGNOSIS; PROTEIN ANALYSIS;

EID: 36048996627     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2007.n.040     Document Type: Article

References (23)

1. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-182.
2. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707-712.
3. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673-1684.
4. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659-1672.
5. Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the Breast Intergroup trial N9831. J Natl Cancer Inst 2002; 94:855-857.
6. Bilous M, Dowsett M, Hanna W, et al. Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol 2003; 16:173-182.
7. Dybdal N, Leiberman G, Anderson S, et al. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat 2005; 93:3-11.
8. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing - National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002; 94:852-854.
9. Lal P, Salazar PA, Ladanyi M, et al. Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification. J Mol Diagn 2003; 5:155-159.
10. Watters AD, Going JJ, Cooke TG, et al. Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat 2003; 77:109-114.
11. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas 1960; 20:37-46.
12. Cicchetti DV, Allison T. New procedure for assessing reliability of scoring EEG sleep recordings. Am J EEG Technol 1971; 11:101-109.
13. Bowker AH. A test for symmetry in contingency tables. J Am Stat Assoc 1948; 43:572-574.
14. Lehmann EL. Nonparametrics: Statistical Methods Based on Ranks. San Francisco, CA: Holden-Day; 1975.
15. Hollander M, Wolfe DA. Nonparametric Statistical Methods. New York, NY: John Wiley and Sons; 1973.
16. Fleiss JL. Statistical Methods for Rates and Proportions. New York, NY: John Wiley and Sons; 1981.
17. Reddy JC, Reimann JD, Anderson SM, et al. Concordance between central and local laboratory HER2 testing from a community-based clinical study. Clin Breast Cancer 2006; 7:153-157.
18. Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 Intergroup adjuvant trial. J Clin Oncol 2006; 24:3032-3038.
19. Anderson S, Gilkerson E, Klein P. Concordance between local labs and a central lab using FISH and IHC for HER2 testing. Poster 22 presented at: 92nd USCAP Annual Meeting; March 22-28, 2003; Washington, DC.
20. Pauletti G, Dandekar S, Rong HM, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000; 18:3651-3664.
21. Press MF, Hung G, Godolphin W, et al. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994; 54:2771-2777.
22. Carlson RW, Moench SJ, Hammond MEH, et al. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw 2006; 4(suppl 3):S1-S22.
23. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Arch Pathol Lab Med 2007; 131:18 [Epub ahead of print].